Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · USD

$10.9

+0.20 (+1.9%)· Recorded snapshot

Market cap	926.5M
Revenue (ttm)	28.7M
Net income (ttm)	-161.1M
EPS (ttm)	-$1.75
Shares out	85.3M
Volume	1,319,218
Beta	1.37

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 28.7M
Net income (ttm): -161.1M
EPS (ttm): -$1.75
Market cap: 926.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-42.7

P25 n/aP50 n/aP75 n/a

ROIC-27.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GLUE indicators

Market & fundamental data

Available fields

198

Groups with data

Currency

USD

Showing 198 of 198 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001826457
Company name	Monte Rosa Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	61225M102
Earnings date	2026-11-09
Earnings time	bmo
Employees	173
Employees change	31
Employees growth	21.83%
Enterprise value	$343.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2021-06-24
Is primary listing	Yes
Is SPAC	No
ISIN number	US61225M1027
Last 10-K release date	2026-03-17
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$926.5M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$10.86
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	GLUE
U.S. state	Massachusetts
Website	https://www.monterosatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-16.07%
EV/Sales	11.66x
FCF / EV yield	-9.58%
FCF yield	-3.49%
Forward EV/Sales	5.16x
Forward P/S	14.13x
P/B ratio	1.86x
P/S ratio	31.96x
Price / tangible book value	1.88x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-633.04%
Pretax margin	-570.8%
Profit per employee	$-931,306
Revenue per employee	$166,052
ROA	-21.63%
ROA (5Y)	-18.15%
ROCE	-28.8%
ROE	-42.66%
ROE (5Y)	-37.72%
ROIC	-27.24%
SBC / revenue	71.68%
Tax / revenue	-9.95%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
Net income growth years	2
Revenue growth	-83.86%
Revenue growth (Q)	-61.34%
Revenue growth (QoQ)	113.02%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-8M
Depreciation and amortization	$8.1M
EBIT	$-181.9M
EBITDA	$-173.7M
EPS	$-1.75
FCF per share	$-0.38
Financing cash flow	$361.5M
Free cash flow	$-32.1M
Free cash flow minus SBC	$-52.7M
Gross profit	$-133.6M
Income taxes	$-2.9M
Investing cash flow	$-316.8M
Net cash flow	$20.7M
Net income	$-161.1M
Operating cash flow minus SBC	$-44.7M
Operating income	$-181.9M
Revenue	$28.7M
Stock-based compensation	$20.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.09
Book value per share	$5.72
Debt / equity	0.08
Long-term assets	$59.8M
Long-term liabilities	$144.2M
Net cash (debt)	$583.1M
Net cash / market cap	63.52%
Net cash growth	133.75%
Net debt / equity	-1.2
Piotroski F-Score	2
Property, plant and equipment	$54M
Shareholders' equity	$487.3M
Tangible book value	$487.3M
Tangible book value per share	$5.72
Total assets	$691.2M
Total cash	$621.1M
Total debt	$38M
Total liabilities	$203.9M
WACC	11.31%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.05
Current assets	$631.4M
Current liabilities	$59.7M
Current ratio	10.58
Net working capital	$-44.7M
Quick ratio	10.49
Working capital	$571.7M
Working capital turnover	0.07

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-11.91%
Dividend yield	0%
Shareholder yield	-11.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$16.94
1D price change	1.88%
1M price change	-8.92%
1M total return	-8.92%
1W price change	-5.63%
1W total return	-5.63%
1Y price change	-12.99%
1Y return CAGR	-13%
1Y total return	-12.99%
20-day SMA	$10.49
200-day SMA	$17.51
3M price change	-52.48%
3M total return	-52.48%
3Y price change	285.61%
3Y return CAGR	56.8%
3Y total return	285.61%
50-day SMA	$12.25
50-day SMA vs 200-day SMA	50under200
52-week high	$25.77
52-week high date	2026-01-08
52-week low	$9.68
52-week low date	2026-10-07
5Y price change	-58.99%
5Y return CAGR	-16.33%
5Y total return	-58.99%
6M price change	-44.43%
6M total return	-44.43%
All-time high	$45.56
All-time high date	2021-09-07
All-time low	$2.44
All-time low date	2023-10-25
Average true range (ATR)	$0.61
Average volume	1.6M
Beta (1Y)	2.37
Beta (2Y)	1.4
Beta (5Y)	1.37
Change from 52-week high	-57.86%
Change from 52-week low	12.19%
Change from all-time high	-76.47%
Change from all-time low	339.34%
Change from open	0.74%
Day's gap	1.13%
Dollar volume	$14.3M
High price	$10.87
Low price	$10.49
Monthly RSI	46.79
Open price	$10.78
Position in 52-week range	97.37%
Premarket change	1.31%
Premarket close	$10.66
Premarket price	$10.80
Premarket volume	4K
Previous close	$10.66
Price vs 150-day SMA	-36.72%
Price vs 20-day SMA	2.16%
Price vs 200-day SMA	-38.78%
Price vs 50-day SMA	-12.5%
Relative volume	0.83
Return from IPO open	-51.09%
Return from IPO price	-43.37%
RSI	44.04
Sharpe ratio	0.16
Sharpe ratio (3Y)	0.87
Sharpe ratio (5Y)	0.26
Sortino ratio	0.35
Sortino ratio (3Y)	1.73
Sortino ratio (5Y)	0.51
Volume	1.3M
Weekly RSI	37.2
YTD price change	-31.63%
YTD total return	-31.63%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	54.5M
Float percentage	63.85%
Shares change (QoQ)	1.6%
Shares change (YoY)	11.91%
Shares held by insiders	0.53%
Shares held by institutions	80.73%
Shares outstanding	85.3M
Short % of float	37.93%
Short % of shares	24.22%
Short ratio	14 days

Deeper analysis on GLUE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this GLUE report

Is a complete GLUE research report available?

No complete published report is available for Monte Rosa Therapeutics, Inc. (GLUE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Monte Rosa Therapeutics, Inc. (GLUE)

Price

Financial snapshot

Fair-value bridge

Latest news · GLUE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GLUE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on GLUE

Frequently asked questions